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Ectopic cell cycle events (CCEs) in postmitotic neurons link the neurodegenerative process in human Alzheimer’s disease (AD)
with the brain phenotype of transgenic mouse models with known familial AD genes. Most reports on the mouse models use
the appearance of brain amyloid pathology as a key outcome measure. In the current paper, we focus on the induction of
neurodegeneration using CCEs as markers for impending neuronal loss. We compare 5 mouse models of familial AD for the
appearance of CCEs in subcortical regions—deep cerebellar nuclei, amygdala, locus coeruleus, hippocampus, and dorsal raphe.
WeﬁndthatthemodelsdiﬀerintheirCCEinvolvementaswellasintheappearanceofphosphorylatedtauandamyloiddeposition,
suggesting that each model represents a diﬀerent disease phenotype. Comparison with the pattern of neuron death in human AD
suggests that each may represent a distinctly diﬀerent disease model when used in preclinical trials.
1.Introduction
Alzheimer’sdisease(AD)isadevastatinglate-onsetneurode-
generative condition that aﬀects many regions of the human
brain. Although the most obvious disease symptoms involve
the inability to form and store new memories, the neuro-
logical and psychiatric description of an individual with AD
includes a wide range of symptoms such as depression, apa-
thy, episodic behavioral outbursts, deteriorating executive
functioning, and others. The biological substrates of these
symptoms are only partially understood, but imaging and
neuropathological studies have revealed important facets of
their diverse and distributed nature. There is a clear loss
of volume and pathologically visible degeneration in the
brain’s memory centers, which include the entorhinal cortex,
hippocampus, and basal forebrain nucleus. But there are
also functional and structural abnormalities found in the
locus coeruleus, dorsal raphe, cingulate gyrus, amygdala and
prefrontal cortex as well as other cortical and subcortical
regions [1–3]. Amyloid plaques and neuroﬁbrillary tangles
arethewidelyacceptedbiochemicalsignaturesofAD,usedto
conﬁrm the clinical diagnosis upon ﬁnal neuropathological
examination. These plaques and tangles are found in con-
junction with signiﬁcant and progressive neurodegeneration
aﬀectingbothsynapsesandcellbodies.Whiletheappearance
of the abnormal deposits is disease speciﬁc, their anatomical
locations in human AD mark only a subset of the brain
regions that are identiﬁed as undergoing signiﬁcant atrophy
during the progress of the disease.
Recent work from our laboratory and many others has
explored the use of abnormal neuronal cell cycle processes
as an additional pathological marker of disease [4–11]. The
timing and location of neuronal cell death in AD has been
intimately associated with the unscheduled appearance of
events related to mitotic cell division. Both cell cycle-related
proteins and evidence of DNA replication have been found
in neurons that are considered “at risk” for death. It is
hypothesized that, although the neurons are able to initiate
a true cell cycle and replicate most if not all of their genome,
they are incapable of completing the process and are believed
to die [12]. Using immunohistochemical analysis, cell cycle
events (CCEs) have been identiﬁed in subcortical brain2 International Journal of Alzheimer’s Disease
Table 1: Transgenic mouse lines used in this study.
Transgenic lines Strain Approach Mutation Promoter Aβ deposits
(age of onset)
Age of analysis
(this study)
R1.40 B6.129-Tg (APPSw)
40Btla/J YAC Genomic Swedish APP Human APP 14months 1 yr; 2 yrs
Tg2576 B6 SJL-Tg (APPsw) cDNA (695) Swedish APP Hamster PrP 9–12 months 9–11 months
Tg6799 (5xTg)
B6SJL-Tg (APPSwFlLon,
PSEN1∗M146L∗L286V)
6799Vas/J
Pronuclear
coinjection:APP and
PS1 transgenes
Swedish, Florida and
London APP &
human PS1
Murine
Thy-1 3 months 6 months
APP8.9 B6.129S2-Tg (APP)
8.9Btla/J YAC Genomic Wt huAPP Human APP
N/A; same as
mouse APP
expression
14 months
APP/PS1 B6.CgTg (APPswe,
PSEN1dE9) 85Dbo/J cDNA Swedish/human PS1 Murine PrP 6 months 6-7 months
regions of individuals with AD as well as those with mild
cognitive impairment (MCI—considered by many to be the
clinical precursor of AD) [11]. In age-matched controls and
in AD brain regions where neurons are not susceptible to
death, cell cycle-related protein expression is signiﬁcantly
lower. This has led to the hypothesis that cell cycle events
represent the ﬁrst step of a process that leads to neuronal cell
death in AD.
Signiﬁcantly, these unexpected attempts by neurons to
reenter a cell cycle provide one of the few homologies ob-
served between mouse models of AD and the pathogenesis
of the human condition. A number of diﬀerent AD models
havebeencreated,mostofwhichrelyontransgenesencoding
the gene for β-amyloid precursor protein (APP), presenilin-
1( PSEN1)o rb o t h[ 4]. Produced in a number of diﬀerent
laboratories,thesemodelsreproducetheplaquepathologyof
AD and lead to modest behavioral abnormalities. However,
none producestheneuroﬁbrillarytangles ofADorthesevere
behavioral changes that mark the end stages of the human
disease. Other researchers have developed models of human
tauopathies based on transgenes expressing disease causing
variants of the microtubule-associated protein tau [13, 14].
Paradoxically, despite the fact that familial AD has not
been signiﬁcantly associated with tau (MAPT) mutations in
humans, the tauopathy mouse models have been reasonably
successful in reproducing many of the pathological charac-
teristics of AD. With age, the brains of these animals display
both tangles of hyperphosphorylated tau and progressive
neurodegeneration in some cases [15]. Thus, MAPT models
reproduce the tangles and degeneration but not the plaques,
while the APP/PS1 models reproduce the Alzheimer’s
plaques but not the associated tangles or neurodegeneration.
From the standpoint of the plaques and tangles, therefore,
the APP/PS1 mice are the better genocopies of AD while the
MAPT mice are somewhat better phenocopies.
We have elected to focus on the pattern of neurode-
generation in APP transgenic mice in order to expand the
characterization of this group of AD models, and we have
usedCCEsasoutcomemeasures.Previously,wheretheyhave
been studied in depth, the appearance of CCEs in many
human disease models show an age-dependent increase in
prevalence that often closely mimics the pattern of neuronal
cell death in the human disease. For example, there is a sig-
nificant correlation between the regional pattern of cell loss
in human ataxia-telangiectasia and its mouse model [16].
The same is true for amyotrophic lateral sclerosis [17]. For
human AD, the temporal and spatial appearance of CCEs in
the R1.40 AD mouse model [18–20] accurately recapitulate
the anatomical progression of cell death in the human. In the
c u r r e n ts t u d y ,w ee x p a n dt h eu s eo fc e l lc y c l em a r k e r sa sa
benchmark of neuronal distress in the mouse. Our goal was
to determine the phenotypic variability among the various
mouse models of AD and to learn whether the similarities
and diﬀerences observed are informative as to their relative
ﬁdelity to the human disease. We were particularly interested
in exploring the involvement of the subcortical areas aﬀected
in AD since these regions typically receive less attention yet
are likely to contribute signiﬁcantly to the symptoms of AD.
We focused our eﬀorts on ﬁve of the many models avail-
able.Wedescribeapatternofselectiveneuronalvulnerability
similar to human AD which is recapitulated in some, but not
all of the ﬁve.
2.MaterialandMethods
2.1. Transgenic Mouse Models of AD. Five transgenic mouse
models of familial AD were used in the current studies.
In each model, amyloid plaques induced by APP develop
at different ages. Detailed information about the mouse
strains is summarized in Table 1. Most animals (R1.40
B6.129-Tg(APPSw)40Btla/J, APP/PS1 B6.Cg-Tg(APPswe,
PSEN1dE9)85Dbo/J, APP8.9 B6.129S2-Tg(APP)8.9Btla/J
and wild type) were housed at Rutgers University Animal
Center. Brain tissues from the Tg2576 and Tg6799 mouse
models were a generous gift from Dr. R. Vassar (North-
western University). Three animals from the R1.40, Tg2576,
and Tg6799 lines were examined for this study. Two each of
the 8.9, APP/PS1 and wild-type strains were used.
2.2. Histology. Animals were anesthetized with Avertin
(0.02cc/g body weight) and perfused through the heart
with 0.1M phosphate-buﬀered saline (PBS), followed by
4% paraformaldehyde in 0.1M PBS solution. The brain
was immediately removed from the skull and transferredInternational Journal of Alzheimer’s Disease 3
to 4% paraformaldehyde at 4◦C overnight. The brains were
then cryoprotected by sinking in 30% sucrose in 0.1M
PBS at 4◦C overnight. After cutting along the midline, the
brains were embedded in OCT compound (Tissue-Tek).
Cryostat sections were cut at 10 microns and air-dried on
Superfrost/Plus glass slides overnight.
For hematoxylin staining, sections were washed in PBS
with 0.25% Tween-20 and rinsed in PBS. They were exposed
to hematoxylin for 45–60sec then washed with double dis-
tilled water until clear. Sections were dehydrated through
graded ethanol and two washes of xylene. VectaMount was
used to mount slides.
2.3. Immunohistochemistry. A rabbit monoclonal antibody
(Abcam, Cambridge, UK) to proliferating cell nuclear anti-
gen (PCNA) was diluted 1:3000 in 10% goat serum/PBS
blocking buﬀe rb e f o r eu s e .Ar a b b i tp o l y c l o n a lc y c l i nAa n -
tibody (Abcam, Cambridge, UK) was used at a working
dilution of 1:500. The beta amyloid, 1–16 (6E10) mouse
monoclonal antibody (Covance, Princeton, NJ), was used at
a working dilution of 1:3000. The anti-PHF-tau antibody
clone AT8 mouse monoclonal antibody (Thermo Scientiﬁc,
Rockoﬀ, IL) was used at a working dilution of 1:1000.
To perform ﬂuorescent immunohistochemistry, sections
were ﬁrst rinsed twice in PBS, followed by pretreatment in
AntigenUnmaskSolution(VectorLaboratories,Burlingame,
CA; working dilution 1:100) for 4-5min at 95◦C. After the
slides had cooled in buﬀer for 10–20min at room tempera-
ture,theywererinsedtwiceindoubledistilledH2O. For DAB
staining, slides were subjected to an additional pretreatment
step: 0.3% hydrogen peroxide in double distilled water for
30min to remove endogenous peroxidase activity. Slides
were then rinsed again in double distilled H2O followed by
PBS. Subsequently, all sections were washed with PBS and
incubated for 1h at room temperature in 10% goat serum
and 0.25% Tween-20 in PBS to block nonspeciﬁc binding.
All primary antibodies, diluted in PBS containing 0.25%
Tween-20 and 10% goat serum, were applied to sections
and then incubated overnight at 4◦C. After rinsing in three
washes of PBS, they were incubated for 1h with a secondary
antibody, which was conjugated with ﬂuorescent Alexa dyes
(dilution, 1:500). The sections were rinsed with another
three washes of PBS. Antifade with DAPI was applied before
sealingthesectionsunderaglasscoverslip.ForDABstaining,
secondary antibody (1:500 dilution) was applied for 1h at
room temperature, washed three times in PBS, and incu-
bated in Vectastain ABC Elite reagent (Vector Laboratories,
Burlingame, CA) for thirty minutes. After three more PBS
washes, slides were developed using diaminobenzidine
(DAB), following the manufacturer’s protocol. Sections were
dehydrated through double distilled water, graded ethanol,
and washed twice in xylene. All sections were mounted in
VectaMount under a glass coverslip. Control sections were
subjected to the same staining procedure, except that pri-
mary antibody was omitted. Positive controls were obtained
using cerebellar cortex of 15-day-old wild-type mice.
To analyze the immunocytochemical data in a more
quantitative fashion, we developed a rating scale to rate the
cell cycle, AT-8, and 6E10 markers. Scores were based only
for their expression in the cell body of neurons. The values
assigned to the rating scale were 0 (no staining or very little
staining of cell cycle events), 1 (a few staining of cell cycle
events 5–15%), 2 (low staining of cell cycle events, 15–30%),
3 (moderate staining of cell cycle events 30–50%), and 4
(>50% cell cycle events). Neuronal density was examined
using hematoxylin staining.
3. Results
3.1. Mouse Models. W ec h o s et os t u d yﬁ v ed i ﬀerent mouse
models. The R1.40 YAC transgenic line contains a 650-
kb yeast artiﬁcial chromosome (YAC) with the entire
400-kb huAPP gene modiﬁed with the Swedish mutation
(K670N/M671L). R1.40 mice exhibit a preferential deposi-
tion of Aβ1−42, which results in the appearance of amyloid
deposits in parietal cortex beginning at 13.5–14 months.
In addition, the R1.40 cortex displays extensive neuritic
abnormalities as evidenced by staining with APP, ubiquitin,
neuroﬁlament, and hyperphosphorylated tau antibodies [21,
22]. Tg2576 is a commonly used AD mouse model. An
APP695 human cDNA transgene was used, with the Swedish
(K670N/M671L) double mutation, under the regulation of
the hamster PrP promoter. The mice develop β-amyloid
deposits at 9–12 months [23]. Tg6799 is also known as the
5xTg transgenic mouse; it carries a single human APP cDNA
with the Swedish K670N/M671L double mutation as well
as the Florida I716V mutation, and the London V717I mu-
tation. An additional human PSEN1 cDNA with M146L
and L286V mutations was also inserted. Both cDNAs are
driven by a mouse Thy-1 promoter. The mice show amyloid
deposition as early as 2 months [24]. The APP/PS1 line was
generated using a mouse prion protein promoter. The trans-
gene includes a cDNA sequence encoding the human APP
gene with the Swedish mutation as well as a PSEN1 cDNA
transgene carrying the ΔE9 mutation (the sequence for exon
9 of PS1 is deleted). These were microinjected together
resulting in the insertion of both APP and PSEN1 transgenes
at a single locus [25]. The APP8.9 line has a YAC genomic
transgene similar to R1.40, but the transgene encodes a wild-
typehumanAPPgeneinsteadoftheSwedishmutationfound
in R1.40. The levels of APP transgene expression have been
found to be similar to both normal levels of APP expression
in humans as well as to the endogenous murine App gene.
Although no plaque pathology has been described, the
APP8.9mouseshouldrecapitulatetheAPPdosageimbalance
f o u n di nD o w nS y n d r o m e[ 26, 27].
3.2. Regional Diﬀerences. We used both DAB and ﬂuores-
cent immunostaining of proliferating cell nuclear antigen
(PCNA) to study the regional variations of CCEs in dorsal
raphe, hippocampus, cerebellum, pons, amygdala, and locus
coeruleus. PCNA is known to play an essential role in po-
sitioning the DNA polymerase in replication and repair of
DNA [28]. Our results were conﬁrmed using cyclin A, the
activating subunit for several of the CDKs (cyclin-dependent
kinases), which served as a second cell cycle marker. As the
cyclin A results were comparable to those with PCNA, only4 International Journal of Alzheimer’s Disease
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Figure 1: Comparison among the mouse lines studied with respect
to the presence of cell cycle events (PCNA), tau-phosphorylation
(AT8), and beta-amyloid plaque deposition (6E10) in the locus
coeruleus. (a) Sagittal section of a wild-type mouse brain indicating
the approximate location of the locus coeruleus. (b) PCNA-positive
neurons are illustrated by their appearance in this representative
sectionfromtheAPP8.9mousemodel.(c)MinorPCNAimmunos-
taining is seen in wild-type mice as illustrated in this representative
micrograph.(d)Quantiﬁcationoftheextentofimmunostainingfor
the cell cycle, phospho-tau, and beta-amyloid plaques in the ﬁve
transgenic models plus wild type.
the PCNA data are shown. The AT8 and 6E10 antibodies
were used to identify neuroﬁbrillary tangles and plaques,
respectively. Immunostaining for tyrosine hydroxylase (TH)
combinedwiththeiranatomicallocationwasusedtoidentify
locus coeruleus neurons. Tryptophan hydroxylase (TpH)
immunoreactivity plus anatomical location was used to
identify the neurons of the dorsal raphe. The results from
the locus coeruleus are illustrated in Figure 1. In 3 of the
5 models—APP/PS1, R1.40 and APP8.9 (Figure 1(b))—
greater than 50% of these brainstem noradrenergic neurons
were found to have immunocytochemical evidence of cell
cycle activity. Tg2576 was much less aﬀected and Tg6799
had evidence of only a few CCEs. No CCEs were detected
in the wild-type locus coeruleus (Figure 1(c)). Despite the
absence of cell cycle activity, Tg6799 scored the highest for
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0
1
2
3
4
5
PCNA AT8 6E10
Wild type
APP8.9
Tg2576
Tg6799
R1.40
APP/PS1
Dorsal raphe
Figure 2: Comparison among the mouse lines studied with respect
to the presence of cell cycle events (PCNA), tau-phosphorylation
(AT8), and beta-amyloid plaque deposition (6E10) in the dorsal
raphe. (a) Sagittal section of a wild-type mouse brain indicating
the approximate location of the raphe in our preparations. (b)
PCNA-positive neurons are illustrated by their appearance in this
representative section from the R1.40 mouse model. (c) Minor
PCNA immunostaining is seen in wild-type mice as illustrated
in this representative micrograph. The insets in both (b) and (c)
are representative ﬁelds at higher magniﬁcation to illustrate the
qualities of the cell cycle staining. (d) Quantiﬁcation of the extent
of immunostaining.
phospho-tau staining, with greater than 50% of the neurons
staining positive. Tg6799 was also the only model to show
6E10 staining in this region (Figure 1(d)); none of the other
four AD models displayed any Aβ plaque deposition in the
brainstem. A graphical summary of the CCEs and associated
amyloid and tau staining patterns is shown in Figure 1(d).
The results from the dorsal raphe are shown in Figure 2.
Most of the tryptophan hydroxylase immunoreactive neu-
rons analyzed were from the region indicated by the box in
Figure 2(a). Of the ﬁve models, R1.40 had the highest CCE
rating (4), with greater than 50% of the neurons scoring
positive for cell cycle staining (Figure 2(b)). APP8.9 had
the second highest level of PCNA staining with moderate
number of neurons positively stained. Age-matched wild-
type mice showed virtually no cell cycle staining in this areaInternational Journal of Alzheimer’s Disease 5
(Figure 2(c)). Similar to our ﬁnding in the locus coeruleus,
AT8 staining was variable and the dorsal raphe of the Tg6799
mouse model showed the highest levels AT8 staining. Across
all genotypes, no correlation was observed between the
CCE score and the presence or absence of AT8 or 6E10
immunoreactivity.
Our analysis of the amygdala was performed in sagittal
sections, which makes the reliable identiﬁcation of the spe-
cific subnuclei more diﬃcult. To address this we divided the
structure into three subregions as illustrated by the black
boxes in Figure 3(a). The anterior region contained pre-
dominantly the anterior cortical amygdaloid nucleus, with
small contributions of the nuclear ansae lenticularis and the
medial and cortical amygdaloid nuclei; the middle region
contained predominantly the posterolateral cortical, with
lesseramounts ofthe anterior-lateralandcentralamygdaloid
nuclei; the posterior region contained predominantly the
posteromedial cortical amygdaloid nucleus with small con-
tributions from the medial basal amygdaloid nucleus. Using
this scheme, regional diﬀerences were found in the involve-
ment of neuronal cell cycle events in the AD models. For all
ﬁve models, the anterior portion of the amygdala demon-
strated lower levels of cell cycle staining, while the medial
and posterior portions showed higher levels of staining. Of
the 5 transgenic models, R1.40 showed the highest level of
immunoreactivity, with greater than 50% of the neurons in
the posterior and medial portions of the amygdala staining
positiveforcellcycleevents.Tg6799hadaslightlylowerCCE
score, followed by APP/PS1. Surprisingly, the wild-type mice
showed modest levels of CCEs in the anterior and medial
portions, but no CCEs in the posterior portions. Tg2576
and APP8.9 showed little staining or no staining in any of
the three regions. In two models, R1.40 and APP/PS1, AT8
was distinctively higher in the posterior and medial regions.
Other models had lower levels of AT8. Amyloid deposits in
the amygdala, as revealed by 6E10 staining, were observed
only in the anterior and medial regions of APP/PS1 mice.
All other regions of the CNS were substantially negative
for cell cycle protein expression, as expected. The one excep-
tiontothiswasasmallregionoftheventralbrainstem.Inthe
pons and the more dorsal nucleus reticulari tegmentis pontis
(NRTP), signiﬁcant cell cycle protein expression was iden-
tiﬁed for all animals. Wild-type animals showed moderate
levels of CCEs, with similar levels in the APP8.9 and Tg2576
APP/PS1 and Tg6799. The only exception to this pattern
was found in the R1.40 model, which had low levels of
CCEs in this region. The R1.40 showed high pontine levels
of hyperphosphorylated tau, but low levels of 6E10-positive
beta amyloid deposits. Tg6799 exhibited a very high level of
6E10 staining—at greater than 50%, the highest score of any
of the models.
In addition to these results, there were observations of
cell cycle staining that were more unexpected. For example,
the deep nuclei of the cerebellum showed strong levels of
CCEs in almost all the models (Figure 4). While AT8 and
6E10 staining was observed only in Tg6799 mice, four out
of ﬁve transgenic models showed moderate CCE staining;
R1.40 showed greater than 50% of the neurons positive for
CCE staining. A more detailed analysis of the involvement of
the cerebellar deep nuclei in the pathogenesis of AD is the
subject of a newly published report [29].
Themostunexpectedﬁnding,however,wasinthehippo-
campal formation. CCEs have been reported in this region
for two mouse models of AD, the PDAPP mouse and the
R1.40 model [18]. In the current study, we did not choose to
explore the PDAPP mice, but were able to replicate our ﬁnd-
ingsintheR1.40(Figure 5(b)).Bothdentategranuleneurons
and pyramidal cells show cell cycle activity. Curiously, none
of the other models we examined had evidence of cell cycle
activity in this region. We observed no signiﬁcant AT8 or
6E10 staining in the dentate gyrus or in the pyramidal cells
of any of the mouse models (Figure 5(d)).
4. Discussion
Transgenic mouse models have long been used to study the
molecular mechanisms of disease. To be considered useful,
such models must recapitulate the human disease in as many
ways as possible, and by this criterion the mouse models of
AD have been at least partially successful. No wild-type
mouse has been reported to naturally develop amyloid pla-
ques, neuroﬁbrillary tangles, or an Alzheimer’s-like loss of
neurons in any brain region. By contrast, mouse lines ex-
pressing APP and/or PSEN1 transgenes with AD-related
mutations display an age-related appearance of β-amyloid
plaques and hyperphosphorylated tau [30]. Behavioral and
neurophysiological abnormalities have also been observed
in some transgenic models, as well as neurophysiological
defects, inﬂammation, and occasionally a decrease in the
numbers of CA1 pyramidal neurons [31]. Impressively, the
YAC R.140 model shows a regional pattern of cerebral and
vascular amyloid deposits along with reactive astrocytes and
microglia that is consistent with the pattern of these events
in human AD. In the end, however, the reproduction of the
human disease has been incomplete in all of these lines.
No neuroﬁbrillary tangles are found; neurodegeneration is
limited even in the best models; and the behavioral changes
aremildcomparedtothoseobservedinhumanswithmid-to
late-stage Alzheimer’s disease. Also, because most successful
APP-expressing mouse lines require highly elevated levels
of transgene expression to form plaques, the use of plaque
deposition as the major outcome measure for evaluating the
eﬀectiveness of the models represents somewhat of a self-
fulﬁlling prophecy [32]. This raises concerns that the effect-
ivenessofthecurrentAPP-basedADmousemodelsmightbe
compromised.
One of these concerns that we attempt to address here
is the poor reproduction in the mouse of the neuronal
cell death found in AD. In human AD, there is a massive
degeneration of neurons and this is observed in a pattern
with pronounced temporal and regional variability [33].
While the reasons for the discordance between mouse and
human phenotypes are unknown, if CCEs are used in place
of actual neuronal cell loss as an index of neurodegeneration,
ourpreviousstudiesoftheR1.40modelsuggestaremarkably
faithful replication of the progression of neuronal cell death
in human AD. What remains unknown is why, if CCEs are
correlated with neuronal cell death, the subsequent death of6 International Journal of Alzheimer’s Disease
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Figure 3: Comparison among the mouse lines studied with respect to the presence of cell cycle events (PCNA), tau-phosphorylation (AT8),
and beta-amyloid plaque deposition (6E10) in the amygdala. (a) Sagittal section of a wild-type mouse brain indicating the approximate
location of the amygdala. The three black boxes indicate the regions identiﬁed as anterior (left), middle (center) and posterior (right). (b)–
(g) Representative ﬁelds illustrating the involvement of cell cycle processes in the three regions. The insets are representative ﬁelds shown
at higher magniﬁcation to illustrate the qualities of the cell cycle staining. Anterior amygdala for R1.40 (b) and wild-type (e) mice contains
the lowest density of CCEs. Middle regions of the amygdala in R1.40 (c) and wild-type (f) mice show increased staining in most models.
PosterioramygdalainR1.40(d)butnotwildtype(g)animalsalsoshowcellcycleactivity.(h)Quantiﬁcationoftheextentofimmunostaining
for the cell cycle, phospho-tau, and beta-amyloid plaques in the ﬁve transgenic models plus wild type.International Journal of Alzheimer’s Disease 7
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Figure 4: Comparison among the mouse lines studied with respect
to the presence of cell cycle events (PCNA), tau-phosphorylation
(AT8),andbeta-amyloidplaquedeposition(6E10)inthedeepcere-
bellarnuclei.(a)Sagittalsectionofawild-typemousebrainindicat-
ing the approximate location of the deep nuclei. (b) PCNA-positive
neurons are illustrated by their appearance in this representative
section from the Tg2576 mouse model. (c) Curiously, some PCNA
immunostaining is also seen in wild-type mice as illustrated in
this representative micrograph. The insets in both (b) and (c) are
representative ﬁelds shown at higher magniﬁcation to illustrate the
qualitiesofthecellcyclestaining.(d)Quantiﬁcationoftheextentof
immunostaining for the cell cycle, phospho-tau, and beta-amyloid
plaques in the ﬁve transgenic models plus wild type.
neuronsisnotimmediate.Indeed,studiesinbothmouseand
human suggest that cell cycling and cell death can be months
apart [19, 34].
To the appearance of cell cycle events, we add the cor-
relation with more traditional neuropathological indicators
of Alzheimer’s disease. Our ﬁndings show that β-amyloid
deposits appear in several subcortical regions—not just in
the R1.40 mouse [34], but in most models. The anatomical
distribution of the deposits, however, is not identical. β-
amyloid deposition appears in some but not all of the struc-
tures studied and some but not all of the models stain with
the AT8 phospho-tau antibody. Based on the models we
examined, it would appear that amyloid deposits and tau
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Figure 5: Comparison among the mouse lines studied with respect
to the presence of cell cycle events (PCNA), tau-phosphorylation
(AT8), and beta-amyloid plaque deposition (6E10) in the hippo-
campus. (a) Sagittal section of a wild-type mouse brain indicating
the approximate location of the areas illustrated in (b) and (c).
(b) PCNA-positive neurons are illustrated by their appearance in
this representative section from the R1.40 mouse model. Note the
involvement of a subset of the dentate granule cells as well as a
few CA4 pyramidal neurons (arrows). (c) Minor PCNA immun-
ostaining is seen in wild-type mice. The insets in panels (b) and (c)
represent higher magniﬁcation of the CA2 region of their respective
mouse model. (d) Quantiﬁcation of the extent of immunostaining
for the cell cycle, phospho-tau, and beta-amyloid plaques in the ﬁve
transgenic models plus wild type. Note that only the R1.40 model
showed cell cycle protein expression at the ages we examined.
expression levels showed region- and model-speciﬁcity and
thus cautions should apply.
In this study, we have expanded the range of biological
responses in the 5 diﬀerent AD mouse models to include
cell cycle events (CCEs) as direct cell-autonomous indices
of neuronal distress. Since CCEs have been observed in both
the human AD brain and in the analogous regions of certain
AD mouse models, characterizing CCE expression patterns
provides a logical and independent outcome measure for the
study of neuronal death process in human AD. It is signif-
icant, therefore, that the results reported here demonstrate
clear diﬀerences among the mouse models examined in the
pattern of CCE expression. We ﬁnd a high level of CCEs in8 International Journal of Alzheimer’s Disease
the brain stem of all 5 models, including the pons, locus
coeruleus, dorsal raphe, and deep nuclei of the cerebellum.
The consistent appearance of CCEs in these more caudal
r e g i o n so ft h eC N Sd e s p i t ed i ﬀering transgene properties
and β-amyloid and tau pathologies is signiﬁcant. It implies
that the existence of neuronal stress in metencephalic and
myelencephalic regions in familial AD may represent a
centralfeatureofdiseasepathogenesis.Thisisconsistentwith
previous suggestions arising from entirely diﬀerent lines of
evidence. Immunocytochemical and biochemical techniques
revealed that cells produced from a locus coeruleus-derived
cell line, but not hippocampal and cortical neurons, exhib-
ited beta-amyloid accumulation and concentrate β-secretase
at process terminals [35]. In the same study, it was shown
that intracellular Aβ plaques can become extracellular when
neurites degenerate, which leads to additional accumulation
and extracellular aggregation. In a diﬀerent domain, the
locus coeruleus has been proposed to play a role in brain in-
ﬂammatory processes, such as those seen in AD [36, 37].
More recently, Braak and Tredici, using tau phosphorylation
as an index, also report very early disease pathology in the
locus coeruleus [38].
The pattern of CCEs in the amygdala suggests internal
variations in AD pathology in this structure such as is seen
in the cortex. In several AD models, the posterior and central
amygdaloid nuclei showed stronger levels of CCE expression
when compared to more anterior amygdaloid neurons, sug-
gesting a common impact of APP transgene expression in
this region. This variation is not apparent in the 6E10 or AT8
staining suggesting that speciﬁc neuroanatomical pheno-
types may be uncovered when CCE markers are used. Our
ﬁndings in the AD mouse models are consistent with the
well-documented involvement of the structurein human AD
pathology [39–41].Thesestudies have shown thatsigniﬁcant
numbers of neurons in the amygdala die during the early
stages of AD. Although there is less information available on
the regional variability within the amygdala, attempts have
been made to use degeneration in this structure to detect the
onset of AD [34, 42].
The R1.40 model showed the strongest staining for CCEs
in most subcortical regions and was the only model in the
current study to show signiﬁcant CCE expression in the
hippocampal region. The absence of CCE expression in the
4 other AD models we studied is noteworthy, albeit without
explanation. Nearly all of the models we studied have been
shown to have deﬁcits in behavioral tasks that are known
to involve the hippocampus. This discordance between
function and pyramidal cell body neuropathology suggests
several hypotheses, none of which are mutually exclusive.
Perhaps the behavioral changes are due to synaptic loss or
atrophy [43], but the cell body, as seen through the appear-
ance of CCEs or neuronal cell death, remains largely unaf-
fected. A related hypothesis is that the transgene-dependent
excess of Aβ at the synapse is the cause of the behavioral
andphysiologicalchanges.Aβ,especiallythelowermolecular
weight form, is recognized as having a neuromodulatory
function[44].Finally,astheagesoftheanimalsweexamined
weremostlyoneyearorless,itisalsopossiblethatthedisease
process in the hippocampus was not suﬃciently advanced at
the time of perfusion.
All of these alternatives are consistent with the proposal
that Alzheimer’s begins as a synaptic disease. What is un-
known at present is whetherthese synaptic problems precede
the CCEs. This would appear to be the situation in hippo-
campus where slices, isolated in vitro, show impaired LTP
[45]; whether this accounts for all of the behavioral changes
or whether some might be due to the aberrant cell cycle ac-
tivity is unknown at this time.
Although no single mouse model provides a complete
recapitulation of human AD, based on the regions we exam-
ined, the YAC R1.40 would appear to be the most reliable
model, especially when using CCEs as an outcome measure.
OnepossibleexplanationforR1.40’sstrongﬁdelityasamod-
el is the close reproduction of the pattern of transgenic APP
expressiontothatfoundinhuman.Thisinturnismostlikely
due to the method used to insert the mutant gene [21, 22].
With the exception of APP8.9, the other transgenes encode
a single splice form of the human APP cDNA. The R1.40
mouse model carries the entire human APP gene, including
all introns and all 3  and 5  regulatory elements within 30–
50 kb of the coding sequence. This allows for a more faithful
temporal and spatial expression pattern, possibly contribut-
ing to a more faithful reproduction of the human disease.
5. Conclusions
We have shown here that CCE markers are a reasonable
way of studying AD mouse model ﬁdelity to human AD.
Since no transgenic mouse model is able to perfectly cap-
ture the complexities of the human AD pathology, using
several phenotypic markers to study the eﬀects of transgene
insertions is well advised. Distinguishing the role of species
diﬀerences and the eﬀects of transgenes in AD pathogenesis
through rigorous characterization of mouse models and AD
willbeimportanttouncoveringthemechanismsofADpath-
ogenesis and lead to the more rapid identiﬁcation of useful
therapeutic targets.
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